OncLive: Dr. Mesa on the rationale for the earlier use of ruxolitinib in myelofibrosis

In this video, Ruben A. Mesa, MD, FACP, executive director of the Mays Cancer Center, discusses the rationale for the earlier use of ruxolitinib (Jakafi) in myelofibrosis.

Watch the interview.